This trial is testing a new cancer treatment that targets two proteins involved in cancer growth. The study will help researchers learn if the treatment is safe and effective.
- Locally Advanced or Metastatic Cancers
- Metastatic Human Papillomavirus-Related Cancer
2 Primary · 11 Secondary · Reporting Duration: Up to 90 days following last dose
2 Treatment Groups
Part A - Dose Escalation
1 of 2
Part B - Dose Expansion
1 of 2
55 Total Participants · 2 Treatment Groups
Primary Treatment: TST005 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many research participants are involved in this experiment?
"Affirmative, clinicaltrials.gov contains evidence that this scientific experiment is currently enrolling subjects. This trial was originally posted on June 11th 2021 and has since been modified as recently as November 1st 2021. A total of 55 patients will be recruited from 3 different sites for participation in the study." - Anonymous Online Contributor
Is this clinical research actively recruiting participants?
"Clinicaltrials.gov conveys that this medical trial is currently enrolling patients. This study was first announced on June 11th 2021 and has since been revised as of November 1st, 2021." - Anonymous Online Contributor
What are the fundamental aims of this research initiative?
"The primary aim of this medical trial, observed over a period of 90 days following the last drug dosage, is to identify both the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dosage (RP2D). Secondary endpoints include determining the Disease Control Rate (DCR), Overall Survival rate (OS) and Time To Maximum Observed Serum concentration for TST005." - Anonymous Online Contributor
Has TST005 received the go-ahead from the FDA?
"There is limited evidence on TST005's safety and efficacy, leading to it receiving a rating of 1." - Anonymous Online Contributor